Successful treatment of recurrent lupus enteritis with rituximab

Lupus

Volumn 19, Issue 2, 2010, Pages 220-222

  Oh, J S ^a   Kim, Y G ^b   Lee, S G ^b   Lee, C K ^b   Yoo, B ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CD19 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; INFUSION FLUID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; RO ANTIBODY;

ABDOMINAL PAIN; ADULT; ASCITES; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENTERITIS; FEMALE; HUMAN; HYPOCOMPLEMENTEMIA; INTESTINE FUNCTION; LETTER; LUPUS ENTERITIS; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RECURRENT LUPUS ENTERITIS; RELAPSE; REST; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ENTERITIS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; KOREA; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHYLPREDNISOLONE; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76049096109     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309345787     Document Type: Letter

References (6)

1. Sultan SM, Ioannou Y., Isenberg DA A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999 ; 38: 917-932. (Pubitemid 29505072)
2. Sanchez-Guerrero J., Reyes E., Alarcon-Segovia D. Primary antiphospholipid syndrome as a cause of intestinal infarction. J Rheumatol 1992 ; 19: 623-625.
3. Kim YG, Ha HK, Nah SS, Lee CK, Moon HB, Yoo B. Acute abdominal pain in systemic lupus erythematosus: factors contributing to recurrence of lupus enteritis. Ann Rheum Dis 2006 ; 65: 1537-1538. (letter).
4. Waite L., Morrison E. Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy). Lupus 2007 ; 16: 841-842.
5. Garcia-Carrasco M., Jimenez-Hernandez M., Escarcega RO, Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009 ; 8: 343-348.
6. Ng KP, Cambridge G., Leandro MJ, Edwards JC, Ehrenstein M., Isenberg DA B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007 ; 66: 1259-1262.